Catalyst Pharmaceuticals Inc.

5.68-0.1300-2.24%Vol 1.06M1Y Perf 29.95%
Jun 15th, 2021 16:00 DELAYED
BID5.68 ASK5.69
Open5.83 Previous Close5.81
Pre-Market- After-Market5.72
 - -  0.04 0.70%
Target Price
8.10 
Analyst Rating
Strong Buy 1.00
Potential %
42.61 
Finscreener Ranking
★★★★★     68.52
Insiders Trans % 3/6/12 mo.
-/-100/33 
Value Ranking
★★★★★     69.57
Insiders Value % 3/6/12 mo.
-/-100/68 
Growth Ranking
★★★★★     89.27
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/71 
Income Ranking
 —    -
Market Cap587.11M 
Earnings Rating
Buy
Price Range Ratio 52W %
93.33 
Earnings Date
9th Aug 2021

Today's Price Range

5.615.83

52W Range

2.885.88

5 Year PE Ratio Range

-8.8018.20

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.35%
1 Month
3.09%
3 Months
36.87%
6 Months
49.87%
1 Year
29.95%
3 Years
59.10%
5 Years
628.21%
10 Years
219.10%

TickerPriceChg.Chg.%
CPRX5.68-0.1300-2.24
AAPL129.64-0.8400-0.64
GOOG2 520.66-6.3800-0.25
MSFT258.36-1.5300-0.59
XOM64.332.26003.64
WFC45.460.31000.69
JNJ164.49-0.8800-0.53
FB336.75-0.0200-0.01
GE13.540.07000.52
JPM155.18-2.3900-1.52
Earnings HistoryEstimateReportedSurprise %
Q01 20210.070.0928.57
Q04 20200.090.1122.22
Q03 20200.090.1122.22
Q02 20200.080.0912.50
Q01 20200.090.1011.11
Q04 20190.090.07-22.22
Q03 20190.110.1318.18
Q02 20190.030.10233.33
Earnings Per EndEstimateRevision %Trend
6/2021 QR0.090.00-
9/2021 QR0.1122.22Positive
12/2021 FY0.392.63Positive
12/2022 FY0.5417.39Positive
Next Report Date9th Aug 2021
Estimated EPS Next Report0.09
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume1.06M
Shares Outstanding103.36M
Trades Count9.64K
Dollar Volume6.35M
Avg. Volume1.53M
Avg. Weekly Volume966.38K
Avg. Monthly Volume1.01M
Avg. Quarterly Volume1.37M

Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) stock closed at 5.68 per share at the end of the most recent trading day (a -2.24% change compared to the prior day closing price) with a volume of 1.06M shares and market capitalization of 587.11M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 76 people. Catalyst Pharmaceuticals Inc. CEO is Patrick J. McEnany.

The one-year performance of Catalyst Pharmaceuticals Inc. stock is 29.95%, while year-to-date (YTD) performance is 70.06%. CPRX stock has a five-year performance of 628.21%. Its 52-week range is between 2.88 and 5.88, which gives CPRX stock a 52-week price range ratio of 93.33%

Catalyst Pharmaceuticals Inc. currently has a PE ratio of 8.40, a price-to-book (PB) ratio of 3.32, a price-to-sale (PS) ratio of 5.00, a price to cashflow ratio of 14.70, a PEG ratio of 2.32, a ROA of 45.84%, a ROC of 50.96% and a ROE of 51.90%. The company’s profit margin is 60.11%, its EBITDA margin is 34.40%, and its revenue ttm is $120.14 Million , which makes it $1.16 revenue per share.

Of the last four earnings reports from Catalyst Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.09 for the next earnings report. Catalyst Pharmaceuticals Inc.’s next earnings report date is 09th Aug 2021.

The consensus rating of Wall Street analysts for Catalyst Pharmaceuticals Inc. is Strong Buy (1), with a target price of $8.1, which is +42.61% compared to the current price. The earnings rating for Catalyst Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Catalyst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Catalyst Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.16, ATR14 : 0.22, CCI20 : 70.24, Chaikin Money Flow : 0.04, MACD : 0.21, Money Flow Index : 67.45, ROC : 1.79, RSI : 59.43, STOCH (14,3) : 58.33, STOCH RSI : 0.00, UO : 54.86, Williams %R : -41.67), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Catalyst Pharmaceuticals Inc. in the last 12-months were: Alicia Grande (Option Excercise at a value of $0), Brian Elsbernd (Option Excercise at a value of $0), Charles B. O'Keeffe (Buy at a value of $20 930), Charles B. O'Keeffe (Option Excercise at a value of $0), David S. Tierney (Option Excercise at a value of $0), Donald A. Denkhaus (Option Excercise at a value of $0), Gary Ingenito (Option Excercise at a value of $0), Gary Ingenito (Sold 3 668 shares of value $12 644 ), Patrick J. McEnany (Buy at a value of $44 550), Patrick J. McEnany (Option Excercise at a value of $0), Philip H. Coelho (Option Excercise at a value of $0), Richard J. Daly (Option Excercise at a value of $0), Steven R. Miller (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome.

CEO: Patrick J. McEnany

Telephone: +1 305 420-3200

Address: 355 Alhambra Circle, Coral Gables 33134, FL, US

Number of employees: 76

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

46%54%

Bearish Bullish

52%48%

News

Stocktwits